OptimizeRx Announces Chief Commercial Officer Transition Agreement
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
OptimizeRx ( (OPRX) ) has issued an update.
OptimizeRx Corporation disclosed that on May 11, 2026 it agreed with Chief Commercial Officer Theresa Greco to a separation effective June 15, 2026, with a formal Separation and Advisory Agreement signed on June 1, 2026 and scheduled to become effective June 9, 2026 if not revoked. Under this arrangement, Greco will leave her executive role but continue to provide advisory services for 12 months through June 15, 2027, during which her previously granted equity will continue to vest and she will be eligible for a special bonus if a change in control occurs during the advisory term.
As part of the separation, OptimizeRx will pay Greco 12 months of continued base salary, a lump-sum cash bonus equal to her $209,000 annual bonus target and reimburse COBRA health benefits for up to a year, while both parties grant a general release of claims. The agreement also reinforces business protection covenants, including a 12‑month non-compete and non-solicitation of employees, service providers, customers and other key counterparties, signaling the company’s focus on continuity and safeguarding commercial relationships during the leadership transition.
The most recent analyst rating on (OPRX) stock is a Buy
with a $11.00 price target.
To see the full list of analyst forecasts on OptimizeRx stock,
see the OPRX Stock Forecast page.
Spark’s Take on OPRX Stock
According to Spark, TipRanks’ AI Analyst, OPRX is a Neutral.
The score is driven by improved fundamentals and a low-risk balance sheet, plus earnings-call evidence of margin/EBITDA progress and product traction. These positives are tempered by weak price action and momentum (downtrend across key moving averages), and near-term revenue pressure including a guidance cut and contracted-revenue softness, with valuation not supported by positive P/E or dividends.
To see Spark’s full report on OPRX stock,
click here.
More about OptimizeRx
OptimizeRx Corporation operates in the healthcare technology and digital communications industry, providing solutions that connect life sciences companies, healthcare providers and patients. The company focuses on optimizing prescription workflows, patient engagement and access to therapies, supporting pharmaceutical commercialization and adherence programs across the U.S. healthcare system.
Average Trading Volume: 525,558
Technical Sentiment Signal: Sell
Current Market Cap: $92.89M
For an in-depth examination of OPRX stock, go to TipRanks’ Overview page.
